PDI, Inc. subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR, the first and only microRNA expression classifier, and ThyGenX Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis.
from The Medical News http://ift.tt/1Ah3IEc
from The Medical News http://ift.tt/1Ah3IEc
No comments:
Post a Comment